Now that Adaptive Biotechnologies Corp’s volume has hit 2.48 million, investors get a glimpse of its size.

On Monday, Adaptive Biotechnologies Corp (NASDAQ: ADPT) opened higher 3.10% from the last session, before settling in for the closing price of $8.40. Price fluctuations for ADPT have ranged from $2.28 to $8.95 over the past 52 weeks.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Annual sales at Healthcare sector company grew by 17.92% over the past five years. Company’s average yearly earnings per share was noted 14.71% at the time writing. With a float of $141.74 million, this company’s outstanding shares have now reached $147.77 million.

Let’s look at the performance matrix of the company that is accounted for 619 employees. In terms of profitability, gross margin is 58.17%, operating margin of -86.43%, and the pretax margin is -89.17%.

Adaptive Biotechnologies Corp (ADPT) Insider Updates

A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Adaptive Biotechnologies Corp is 4.61%, while institutional ownership is 92.59%. The most recent insider transaction that took place on Mar 24 ’25, was worth 14,705. Before that another transaction happened on Mar 13 ’25, when Company’s Director sold 36,291 for $7.19, making the entire transaction worth $260,932. This insider now owns 15,394 shares in total.

Adaptive Biotechnologies Corp (ADPT) Performance Highlights and Predictions

According to the Wall Street analysts, stocks earnings will be around 14.71% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 28.67% during the next five years compared to -1.51% drop over the previous five years of trading.

Adaptive Biotechnologies Corp (NASDAQ: ADPT) Trading Performance Indicators

Check out the current performance indicators for Adaptive Biotechnologies Corp (ADPT). In the past quarter, the stock posted a quick ratio of 2.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.19.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.08, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -0.70 in one year’s time.

Technical Analysis of Adaptive Biotechnologies Corp (ADPT)

Adaptive Biotechnologies Corp (NASDAQ: ADPT) saw its 5-day average volume 2.28 million, a positive change from its year-to-date volume of 1.77 million. As of the previous 9 days, the stock’s Stochastic %D was 84.80%. Additionally, its Average True Range was 0.69.

During the past 100 days, Adaptive Biotechnologies Corp’s (ADPT) raw stochastic average was set at 92.62%, which indicates a significant increase from 87.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 86.70% in the past 14 days, which was higher than the 84.74% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $7.74, while its 200-day Moving Average is $5.55. Nevertheless, the first resistance level for the watch stands at $8.97 in the near term. At $9.28, the stock is likely to face the second major resistance level. The third major resistance level sits at $9.55. If the price goes on to break the first support level at $8.39, it is likely to go to the next support level at $8.12. Assuming the price breaks the second support level, the third support level stands at $7.82.

Adaptive Biotechnologies Corp (NASDAQ: ADPT) Key Stats

There are currently 148,582K shares outstanding in the company with a market cap of 1.29 billion. Presently, the company’s annual sales total 178,960 K according to its annual income of -159,490 K. Last quarter, the company’s sales amounted to 47,460 K and its income totaled -33,690 K.